Dengue fever future or investigational therapies

Dengue Fever Microchapters
Home
Patient Info
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Dengue fever from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Dengue fever future or investigational therapies On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Dengue fever future or investigational therapies All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Dengue fever future or investigational therapies
CDC on Dengue fever future or investigational therapies
Dengue fever future or investigational therapies in the news
Blogs on Dengue fever future or investigational therapies
Directions to Hospitals Treating Dengue fever
Risk calculators and risk factors for Dengue fever future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Emerging treatments

Emerging evidence suggests that mycophenolic acid and ribivirin inhibit dengue replication. Initial experiments showed a fivefold increase in defective viral RNA production by cells treated with each drug.^[2] In vivo studies, however, have not yet been done.